- Home
- CTO vs PLRX Comparison
CTO vs PLRX Comparison
Compare CTO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | PLRX |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.9M | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTO | PLRX |
|---|---|---|
| Price | $17.82 | $1.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 11 |
| Target Price | ★ $22.00 | $3.79 |
| AVG Volume (30 Days) | 234.2K | ★ 1.8M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $146,948,000.00 | N/A |
| Revenue This Year | $20.87 | N/A |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.84 | N/A |
| 52 Week Low | $15.07 | $1.10 |
| 52 Week High | $20.88 | $15.00 |
Technical Indicators
Market Signals| Indicator | CTO | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 34.01 |
| Support Level | $17.81 | $1.17 |
| Resistance Level | $18.31 | $1.35 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 39.72 | 15.38 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.